Pictet-Biotech HP CHFRegister to Unlock Ratings |
Performance History | 31/10/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 33.2 | -11.7 | -9.3 | 12.7 | -0.3 | |
+/-Cat | - | - | - | - | - | |
+/-B’mrk | - | - | - | - | - | |
Category: Other Equity | ||||||
Category Benchmark: - |
Key Stats | ||
NAV 21/11/2024 | CHF 653.14 | |
Day Change | 0.94% | |
Morningstar Category™ | Other Equity | |
ISIN | LU0843168732 | |
Fund Size (Mil) 21/11/2024 | USD 1434.27 | |
Share Class Size (Mil) 21/11/2024 | CHF 10.85 | |
Max Initial Charge | 5.00% | |
Ongoing Charge 14/02/2024 | 2.04% |
Investment Objective: Pictet-Biotech HP CHF |
To increase the value of your investment while seeking to achieve a positive social impact. The Fund applies a sustainable strategy and invests at least two-thirds of its net assets in equities or similar securities issued by biopharmaceutical companies throughout the world. Companies supporting the health of people with high innovation capacity. Better therapies can deliver true value to patients and healthcare systems alike. These companies are tackling high unmet medical needs and reduce the pressures on healthcare budgets through the reduction of hospital admissions or symptom management. The Fund invests mainly in companies whose significant proportion of their activities are related to, but not limited to, new mechanisms of actions offering potential cures or management of diseases that were hard to treat before, technology platforms, research tools and services in the biotechnology value chain as well as the improvement of therapies or drugs. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Tazio Storni 26/05/2016 | ||
Marco Minonne 01/06/2020 | ||
Click here to see others | ||
Inception Date 23/10/2012 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
MSCI ACWI NR EUR | - |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Pictet-Biotech HP CHF | 31/10/2024 |
|
|
Top 5 Holdings | Sector | % |
argenx SE ADR | Healthcare | 5.93 |
Gilead Sciences Inc | Healthcare | 4.82 |
Insmed Inc | Healthcare | 4.14 |
Intra-Cellular Therapies Inc | Healthcare | 4.02 |
Sarepta Therapeutics Inc | Healthcare | 3.74 |
Increase Decrease New since last portfolio | ||
Pictet-Biotech HP CHF |